Researchers created a model to examine the three-year clinical and economic impacts of Epigenomics AG’s Epi proColon, fecal immunochemical testing and Exact Sciences’ Cologuard. Epi proColon is a blood-based CRC screening test. Cologuard is a multitarget stool and DNA-based screening test. Researchers used the model to “screen” 34,800 of 81,200 unscreened individuals in a theoretical commercial health plan population.
Researchers said the model showed that the tests helped detect CRC earlier and at curable stages at a similar cost for patients who didn’t want to undergo colonoscopy.
Read the entire study here.
Note: The study was funded by Epigenomics AG, of which two study authors serve as consultants to and one author serves as an employee.
More articles on surgery centers:
Managing anesthesia services in ASCs — 5 top problems + solutions
5 questions to ask ASC anesthesia providers
CRH Medical acquires Florida gastroenterology anesthesia practice — 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
